Shehab Ebrahim, MD
Retina Specialist · Metairie, LANPI 1578556213
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Galderma Laboratories, L.p. at 52.5% of the total. Reporting peaked in 2020 at $150 and has fallen 65.6% since, to $52 in 2025. That places this record below the midpoint for retina specialist clinicians in LA, where the typical reported total is $2,679.
Across 9 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$150
- Novo Nordisk$28
- Genentech USA, Inc.$22
- Astellas Pharma US Inc$20
- Dexcom, Inc.$18
- Regeneron Healthcare Solutions, Inc.$17
- plus $30 from 2 others
What the payments were for
- Speaking & faculty fees$15053%
- Food & beverage$13547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 1 | $150 |
| Novo Nordisk | 2 | $28 |
| Genentech USA, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$285 in reported general payments places this provider in the 5th percentile of 30 retina specialist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 582 | $10,360 |
| Dorzolamide Hcl | 358 | $8,055 |
| Brimonidine Tartrate | 662 | $7,835 |
| RhopressaNetarsudil Mesylate | 21 | $6,557 |
| Latanoprost | 330 | $4,158 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 278 | $3,789 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $2,355 |
| Ketorolac Tromethamine | 19 | $999 |
| Timolol Maleate | 48 | $547 |
| Acyclovir | 16 | $103 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Metairie
- Gwen CousinsMetairie$10K
- Brett BuddenMetairie$6K
- Arley Jaramillo RodriguezMetairie$6K
- Neil NotarobertoMetairie$4K
- Mallika DossMetairie$3K
- Kathy TaMetairie$3K
- Stanislav ZhukMetairie$2K
- Waldemar TorresMetairie$1K
- Jasmine ElisonMetairie$1K
- Ronald WillsonMetairie$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.